Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 11/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 10/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | CSNK1A1L | Q8N752 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.75 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.75 |
| ▸ | GCGR | P47871 | 9/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | FRK | P42685 | 2/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.75 |
| ▸ | GSK3B | P49841 | 2/20 | 0.75 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.75 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.75 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458366 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL9201148 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| Hydrochloric Acid SCHEMBL16566835 | 0.99 | MAPK14 (0.98) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL4552997 | 0.88 | ALOX5 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL5698563 | 0.88 | ALOX5 (0.78) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL6930802 | 0.87 | ALOX5 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL178158 | 0.87 | MAPK11 (0.77) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL19868925 | 0.87 | MAPK11 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL15075603 | 0.87 | MAPK11 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL7484511 | 0.86 | ALOX5 (0.76) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4717765-A1 | METHOD FOR PRODUCING CELL POPULATION CONTAINING CD4 SINGLE POSITIVE HELPER T CELLS FROM PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | UNIV KYOTO (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-3639854-B1 | MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY | THE DOSHISHA (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025242918-A1 | PENTAMIDINE FOR USE IN THE TREATMENT OR PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS CAUSED BY CHLAMYDIA SPP. OR NEISSERIA SPP. | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2025-11-27 | — | — | WO | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | XBP1, HSPA5, DNAJC10 | MAPK14 968/4885MAPK11 271/4885ALOX5 2908/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK11 26/4885ALOX5 2982/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAPK14 14/4885MAPK11 55/4885ALOX5 2922/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK11 26/4885ALOX5 2982/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK14 18/4885MAPK11 2/4885ALOX5 1642/4885 |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK14 13/4885MAPK11 50/4885ALOX5 657/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885MAPK11 24/4885ALOX5 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.